Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Change in Serum Bilirubin Level Predicts Incident Metabolic Syndrome

By LabMedica International staff writers
Posted on 21 Dec 2016
Metabolic syndrome (MetS) is a constellation of interlinked metabolic conditions that seem to accelerate the development of cardiovascular disease. More...
Chronic inflammation, oxidative stress, and insulin resistance all play important roles in the initiation and advancement of MetS.

Serum bilirubin level was negatively associated with the prevalence of MetS in previous cross-sectional studies; however, bilirubin variance preceding the development of MetS has yet to be investigated. An inverse association between mean bilirubin concentrations and the number of metabolic syndrome components in a population with atherogenic dyslipidemia has been reported.

Scientists at the Sungkyunkwan University School of Medicine (Seoul, Republic of Korea) conducted a retrospective longitudinal study of subjects who had undergone at least four yearly health check-ups between 2006 and 2012. Of 24,185 total individuals who received annual check-ups, 11,613 non-MetS participants with a baseline bilirubin level not exceeding 34.2 μmol/L were enrolled. Venous blood samples were obtained after an overnight fast and measurements included serum bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), fasting plasma glucose, plasma insulin, triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum uric acid, and creatinine.

Serum bilirubin concentrations were measured using the diazonium salt/diazonium ion with blank method on a Hitachi-7600, Modular DP-110 autoanalyzer (Hitachi, Tokyo, Japan). Plasma glucose levels were determined using the hexokinase method on an Advia 1650 automated chemistry analyzer, and plasma insulin values were derived using an immunoradiometric assay. Fasting HDL-C, LDL-C, and TG were measured using the enzymatic colorimetric method with a Modular D2400.

The scientists found that during 55,407 person-years of follow-up, 2,439 cases of incident MetS developed (21.0%). There was an increased risk for incident MetS that was observed in higher percent change in bilirubin quartiles, with hazard ratios of 2.415 in men and 2.156 in women in the fourth quartile, compared to the lowest quartile, after adjusting for various variables. The hazard ratios per one standard deviation increase in percent change in bilirubin as a continuous variable were 1.277 in men and 1.366 in women.

The authors concluded that an increase in bilirubin concentration, defined as PCB, was positively associated with incident MetS in a healthy Korean population, indicating that bilirubin increase might precede the development of MetS. Positive levels of PCB may reflect an increase in oxidative stress preceding new-onset MetS. The study was published on December 9, 2016, in the journal Public Library of Science ONE.

Related Links:
Sungkyunkwan University School of Medicine
Hitachi


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.